Skip to main content

Rubicon Genomics Starts SAB For Move Into Drug Development Services

NEW YORK, May 30-Rubicon Genomics said today that it was forming a scientific advisory board to oversee the expansion of OmniPlex, its DNA amplification system.


The company plans to develop and validate its technology for use in whole genome amplification and molecular haplotyping, applications useful in drug development.


The new scientific advisory board includes the University of Michigan's Michael Boehnke, Sensors for Medicine and Science's Anthony Czarnik and the University of Oklahoma's Bruce Roe.


Boehnke, a biostatistician, is director of the University of Michigan Center for Statistical Genetics  and the principal investigator in the Finland-United States Investigation of NIDDM Genetics Study.


Czarnik is chief scientific officer at Sensors for Medicine and Science, a company that is developing a new molecular detection technology. He was previously director of bio-organic chemistry at Parke-Davis and was a co-founder of Illumina.


Roe is director of the University of Oklahoma's Advanced Center for Genome Technology, where he lead a team involved in the Human Genome Project.


Rubicon, founded in 1998 as a spinoff from the University of Michigan, specializes in developing alternatives to PCR. It is based in Ann Arbor, Mich.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.